PMID- 29429551
OWN - NLM
STAT- MEDLINE
DCOM- 20181228
LR  - 20210518
IS  - 2173-5778 (Electronic)
IS  - 2173-5778 (Linking)
VI  - 109
IP  - 4
DP  - 2018 May
TI  - Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer 
      Immunoglobulins.
PG  - 323-330
LID - S0001-7310(17)30661-0 [pii]
LID - 10.1016/j.ad.2017.11.009 [doi]
AB  - Intravenous immunoglobulin (IVIG) replacement therapy has been used in immune 
      deficiency diseases for more than 50 years. The indications for this treatment 
      have evolved, however, and IVIG therapy is now used in various diseases in which 
      the immune system plays a prominent role. IVIG therapy has carved out a niche in 
      dermatology for the treatment of such conditions as dermatomyositis, autoimmune 
      bullous diseases, and toxic epidermal necrolysis. Special attention has been paid 
      to this therapy in recent years. New guidelines have been published and should be 
      taken into consideration in dermatology. This review provides a practical guide 
      to IVIG use in our specialty.
CI  - Copyright (c) 2017 AEDV. Publicado por Elsevier Espana, S.L.U. All rights reserved.
FAU - Navarro-Trivino, F J
AU  - Navarro-Trivino FJ
AD  - Unidad de Dermatologia Medico-Quirurgica y Venereologia, Hospital Comarcal Santa 
      Ana, Motril, Espana. Electronic address: fntmed@gmail.com.
FAU - Perez-Lopez, I
AU  - Perez-Lopez I
AD  - Unidad de Gestion Clinica de Dermatologia y Venereologia, Complejo Hospitalario 
      Universitario de Granada, Granada, Espana.
FAU - Ruiz-Villaverde, R
AU  - Ruiz-Villaverde R
AD  - Unidad de Gestion Clinica de Dermatologia y Venereologia, Complejo Hospitalario 
      Universitario de Granada, Granada, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Dermatologia e inmunoglobulinas.  inverted question markA quien y como administrarlas?
DEP - 20180209
PL  - Spain
TA  - Actas Dermosifiliogr (Engl Ed)
JT  - Actas dermo-sifiliograficas
JID - 101777537
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Autoimmune Diseases/therapy
MH  - Contraindications, Drug
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Infusions, Subcutaneous
MH  - Patient Selection
MH  - Practice Guidelines as Topic
MH  - Premedication
MH  - Skin Diseases/*therapy
OTO - NOTNLM
OT  - Autoimmune bullous diseases
OT  - Dermatology
OT  - Dermatologia
OT  - Dermatomiositis
OT  - Dermatomyositis
OT  - Enfermedades autoinmunes ampollares
OT  - Inmunoglobulinas intravenosas
OT  - Intravenous immunoglobulin therapy
OT  - Necrolisis epidermica toxica
OT  - Toxic epidermal necrolysis
EDAT- 2018/02/13 06:00
MHDA- 2018/12/29 06:00
CRDT- 2018/02/13 06:00
PHST- 2017/04/02 00:00 [received]
PHST- 2017/10/16 00:00 [revised]
PHST- 2017/11/05 00:00 [accepted]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/12/29 06:00 [medline]
PHST- 2018/02/13 06:00 [entrez]
AID - S0001-7310(17)30661-0 [pii]
AID - 10.1016/j.ad.2017.11.009 [doi]
PST - ppublish
SO  - Actas Dermosifiliogr (Engl Ed). 2018 May;109(4):323-330. doi: 
      10.1016/j.ad.2017.11.009. Epub 2018 Feb 9.